Varian Medical Systems

This is a quick demonstration of the Varian Identify image-guided patient positioning system at the American Association ...

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment Services International (CTSI) for $283 million. Privately held, CTSI operates the American Oncology Institute in Hyderabad and 10 multidisciplinary — radiation, medical and surgical oncology — cancer centers across the Indian subcontinent, as well as a U.S.-based Oncology Solutions division that provides cancer care professional services to healthcare providers worldwide.

Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high-dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results — presented at the American Association for Cancer Research (AACR) annual meeting, March 29-April 3 in Atlanta — showed reduced toxicity in healthy tissues and organs.